Patents by Inventor Darryl David DIXON
Darryl David DIXON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10807948Abstract: Disclosed herein are substituted indane derivatives useful as HIF-2? inhibitors. Pharmaceutical compositions comprising said indane derivatives and methods of using said indane derivatives for treating proliferative diseases, such as renal cell carcinoma and von Hippel-Lindau disease, and other conditions associated with HIF-2? activity are also disclosed.Type: GrantFiled: March 4, 2016Date of Patent: October 20, 2020Assignee: PELOTON THERAPEUTICS, INC.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Publication number: 20200190031Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: ApplicationFiled: February 20, 2020Publication date: June 18, 2020Applicant: Peloton Therapeutics, Inc.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Patent number: 10597366Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: GrantFiled: October 18, 2018Date of Patent: March 24, 2020Assignee: Peloton Therapeutics, Inc.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Publication number: 20190119214Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: ApplicationFiled: October 18, 2018Publication date: April 25, 2019Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Publication number: 20190015377Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.Type: ApplicationFiled: July 16, 2018Publication date: January 17, 2019Applicant: Peloton Therapeutics, Inc.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Patent number: 10144711Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: GrantFiled: November 7, 2017Date of Patent: December 4, 2018Assignee: PELOTON THERAPEUTICS, INC.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Patent number: 10040767Abstract: Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the as compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.Type: GrantFiled: May 14, 2015Date of Patent: August 7, 2018Assignee: Peloton Therapeutics, Inc.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Hanbiao Yang
-
Publication number: 20180162807Abstract: Aromatic entities that modulate HIF-2? activity, pharmaceutical compositions containing the aromatic entities, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2? activity are described herein.Type: ApplicationFiled: March 4, 2016Publication date: June 14, 2018Inventors: Darryl David DIXON, Jonas GRINA, John A. JOSEY, James P. RIZZI, Stephen T. SCHLACHTER, Eli M. WALLACE, Bin WANG, Paul WEHN, Rui Xu, Hanbiao YANG
-
Publication number: 20180155279Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: ApplicationFiled: November 7, 2017Publication date: June 7, 2018Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Patent number: 9969689Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: GrantFiled: February 22, 2017Date of Patent: May 15, 2018Assignee: PELOTON THERAPEUTICS, INC.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Patent number: 9908845Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: GrantFiled: September 5, 2014Date of Patent: March 6, 2018Assignee: PELOTON THERAPEUTICS, INC.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Publication number: 20180049995Abstract: Chemical compounds that modulate HIF-2? activity, their polymorphs, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with HIF-2?, are described herein.Type: ApplicationFiled: March 10, 2016Publication date: February 22, 2018Inventors: Darryl David DIXON, Peter J. STENGEL, Bin WANG
-
Patent number: 9896418Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: GrantFiled: February 22, 2017Date of Patent: February 20, 2018Assignee: PELOTON THERAPEUTICS, INC.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Patent number: 9884843Abstract: The present disclosure relates to cyclic sulfones and sulfoximines that are HIF-2a inhibitors and methods of making and using them for treating cancers. In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier or excipient. The compound may exist in an amorphous form, a crystalline form, or as a salt, solvate, or hydrate. In another aspect, the present disclosure provides a method of treating renal cell carcinoma by administrating a therapeutically effective amount of a compound described herein or a pharmaceutical composition thereof to a subject in need of such treatment.Type: GrantFiled: December 15, 2014Date of Patent: February 6, 2018Assignee: PELOTON THERAPEUTICS, INC.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Publication number: 20170217892Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: ApplicationFiled: February 22, 2017Publication date: August 3, 2017Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Publication number: 20170217891Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: ApplicationFiled: February 22, 2017Publication date: August 3, 2017Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
-
Publication number: 20170088523Abstract: Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the as compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.Type: ApplicationFiled: May 14, 2015Publication date: March 30, 2017Inventors: Darryl David DIXON, Jonas GRINA, John JOSEY, James P. RIZZI, Stephen T. SCHLACHTER, Eli M. WALLACE, Bin WANG, Paul WEHN, Hanbiao YANG
-
Publication number: 20160368893Abstract: The present disclosure relates to cyclic sulfones and sulfoximines that are HIF-2a inhibitors and methods of making and using them for treating cancers. In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier or excipient. The compound may exist in an amorphous form, a crystalline form, or as a salt, solvate, or hydrate. In another aspect, the present disclosure provides a method of treating renal cell carcinoma by administrating a therapeutically effective amount of a compound described herein or a pharmaceutical composition thereof to a subject in need of such treatment.Type: ApplicationFiled: December 15, 2014Publication date: December 22, 2016Inventors: Darryl David DIXON, Jonas GRINA, John A. JOSEY, James P. RIZZI, Stephen T. SCHLACHTER, Eli M. WALLACE, Bin WANG, Paul WEHN, Rui XU, Hanbiao YANG
-
Publication number: 20160251307Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: ApplicationFiled: September 5, 2014Publication date: September 1, 2016Applicant: Peloton Therapeutics, Inc.Inventors: Darryl David DIXON, Jonas GRINA, John A. JOSEY, James P. RIZZI, Stephen T. SCHLACHTER, Eli M. WALLACE, Bin WANG, Paul WEHN, Rui XU, Hanbiao YANG
-
Patent number: RE49948Abstract: The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.Type: GrantFiled: February 3, 2022Date of Patent: April 30, 2024Assignee: Peloton Therapeutics, Inc.Inventors: Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang